Brad R Rosenberg | Mount Sinai

Biography

Research Topics

Antivirals, Bioinformatics, Cellular Immunity, Genomics, Hepatitis C Virus, Immunology, Infectious Disease, Interferon, Lymphocytes, RNA, T Cells, Technology & Innovation, Viruses and Virology

Multi-Disciplinary Training Area

Immunology [IMM], Microbiology [MIC]

http://labs.icahn.mssm.edu/rosenberglab/

Multi-Disciplinary Training Area

Microbiology [MIC]

Research

New topic

The Rosenberg laboratory is focused on developing and applying high throughput sequencing and related high dimensional techniques to gain new understandings of immune function in viral infection. Many current projects utilize custom implementations of high throughput single cell RNA-Seq methodologies.

Education

BS, MS, Yale University

PhD, The Rockefeller University

MD, Weill Cornell Medical College

Office Locations

Annenberg Building Floor 17 Room 17-70C

1468 Madison Ave

New York, NY 10029

212-241-0239

Annenberg Building Floor 17 Room 70C

1468 Madison Ave

New York, NY 10029

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Rosenberg during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

Dispatch Biotherapeutics

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

Dispatch Biotherapeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Rosenberg during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

Dispatch Biotherapeutics

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

Dispatch Biotherapeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.